Quick Takeaways
- BBIO - BridgeBio Pharma, Inc. has 21 insiders with reported activity on this page.
- Net insider value flow over the last year: -$482,573,301.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 21 Insiders of BridgeBio Pharma, Inc.
- Symbol
- BBIO on Nasdaq
- Location
- Palo Alto, CA
What Changed
- Buy value: ; sell value: $482,573,300.
- Net share flow: -11,714,548.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$482,573,301.
Buys
$0
Shares: 0
Insiders: 0
Sells
$482,573,301
Shares: 11,714,548
Insiders: 12
Net
-$482,573,301
Shares: -11,714,548
Insiders: -12
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 313,239 | $0 | $21,746,448 | -$21,746,448 |
| 3-6 | 0 | 707,215 | $0 | $48,042,853 | -$48,042,853 |
| 6-9 | 0 | 717,913 | $0 | $35,197,567 | -$35,197,567 |
| 9-12 | 0 | 9,976,181 | $0 | $377,586,433 | -$377,586,433 |
BridgeBio Pharma, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $816,436,500 | -$154,000,000 | -16% | Filing P/S | 27 Jun 2025 |
| KKR Genetic Disorder L.P. | 10%+ Owner | $453,525,208 | -$205,200,000 | -31% | Filing P/S | 12 May 2025 |
| Neil Kumar | Chief Executive Officer, Director | $373,218,808 | -$56,997,703 | -13% | Mixed | 17 Mar 2026 |
| Frank Mccormick | Director | $51,404,193 | -$21,669,537 | -30% | Mixed | 29 Oct 2025 |
| Charles J. Homcy | Director | $44,000,352 | -$13,912,443 | -24% | Filing P/S | 08 Aug 2025 |
| Thomas Trimarchi | President and CFO | $26,748,273 | -$5,103,355 | -16% | Mixed | 18 Mar 2026 |
| Maricel Apuli | Chief Accounting Officer | $9,202,735 | -$403,367 | -4.2% | Mixed | 18 Mar 2026 |
| Brian C. Stephenson | CFO and Treasurer | $6,443,801 | Mixed | 25 Feb 2025 | ||
| Ali J. Satvat | Director | $5,451,210 | Mixed | 20 Jun 2025 | ||
| Andrew Lo | Director | $4,285,707 | -$10,169,562 | -70% | Filing P/S | 17 Nov 2025 |
| James C. Momtazee | Director | $3,122,427 | Mixed | 20 Jun 2025 | ||
| Richard H. Scheller | Director | $2,421,359 | Mixed | 16 Feb 2023 | ||
| Andrea Ellis | Director | $1,205,833 | -$5,402,485 | -82% | Filing P/S | 04 Mar 2026 |
| Randal W. Scott | Director | $1,199,547 | -$1,421,022 | -54% | Mixed | 17 Feb 2026 |
| Ronald J. Daniels | Director | $1,082,695 | -$3,888,999 | -78% | Filing P/S | 06 Nov 2025 |
| Douglas A. Dachille | Director | $873,182 | Mixed | 20 Jun 2025 | ||
| Fred Hassan | Director | $850,194 | Mixed | 20 Jun 2025 | ||
| Hannah Valantine | Director | $564,563 | -$4,404,828 | -89% | Mixed | 10 Mar 2026 |
| Jennifer E. Cook | Director | $451,254 | Mixed | 20 Jun 2025 | ||
| Eric Aguiar | Director | $216,382 | Mixed | 20 Jun 2025 | ||
| Brent L. Saunders | Director | Mixed | 22 Jun 2022 |
Top shareholders of BridgeBio Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
—
mixed-class rows
|
17,653,786
mixed-class rows
|
$1,299,731,745 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
—
mixed-class rows
|
16,634,366
mixed-class rows
|
$1,138,995,616 | — | 31 Dec 2025 | |
| VIKING GLOBAL INVESTORS LP |
13F
13D/G
3/4/5
|
Company · 10%+ Owner |
6.1%
from 13D/G
|
14,393,934
|
$1,100,992,012 | — | 31 Dec 2025 | |
| Kohlberg Kravis Roberts & Co. L.P. |
13F
|
Company |
6.8%
|
13,260,971
|
$1,014,331,672 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13D/G
13F
|
Company |
5.7%
|
11,000,457
|
$845,275,116 | $0 | 31 Dec 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.6%
|
8,998,463
|
$688,292,435 | — | 31 Dec 2025 | |
| KKR Genetic Disorder L.P. |
13D/G
3/4/5
|
10%+ Owner |
7%
|
13,260,971
|
$476,864,517 | -$215,760,000 | 12 May 2025 | |
| Aisling Capital Management LP |
13F
|
Company |
—
mixed-class rows
|
5,654,236
mixed-class rows
|
$396,373,450 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
—
mixed-class rows
|
5,181,144
mixed-class rows
|
$382,342,461 | — | 31 Dec 2025 | |
| Neil Kumar |
13D/G
3/4/5
|
Chief Executive Officer, Director |
5.4%
|
10,466,712
|
$376,382,964 | $0 | 31 Dec 2024 | |
| Invesco Ltd. |
13F
|
Company |
2.5%
|
4,831,305
|
$369,546,521 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
—
mixed-class rows
|
4,974,510
mixed-class rows
|
$351,728,050 | — | 31 Dec 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
—
mixed-class rows
|
19,078,594
mixed-class rows
|
$315,627,997 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
|
Company · T. Rowe Price Associates, Inc. |
1.1%
from 13D/G
|
4,631,880
mixed-class rows
|
$302,918,000 | — | 31 Dec 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.8%
|
3,545,557
|
$271,199,655 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
—
mixed-class rows
|
5,255,734
mixed-class rows
|
$216,050,112 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
—
mixed-class rows
|
2,630,662
mixed-class rows
|
$185,847,322 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.1%
|
2,214,031
|
$169,351,231 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.1%
|
2,164,928
|
$165,595,356 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.1%
|
2,050,746
|
$156,861,562 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
—
mixed-class rows
|
2,243,465
mixed-class rows
|
$153,752,065 | — | 31 Dec 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
—
mixed-class rows
|
2,029,507
mixed-class rows
|
$151,682,238 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1%
|
1,947,047
|
$148,929,625 | — | 31 Dec 2025 | |
| Capital Research Global Investors |
13F
|
Company |
1%
|
1,934,698
|
$147,985,050 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
—
mixed-class rows
|
1,969,034
mixed-class rows
|
$144,638,596 | — | 31 Dec 2025 | |
| SC US (TTGP), LTD. |
13F
|
Company |
0.96%
|
1,860,364
|
$142,299,242 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
—
mixed-class rows
|
1,877,484
mixed-class rows
|
$137,553,928 | — | 31 Dec 2025 | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. |
13F
|
Company |
0.89%
|
1,725,266
|
$131,966,000 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.87%
|
1,680,972
|
$128,577,548 | — | 31 Dec 2025 | |
| Laurion Capital Management LP |
13F
|
Company |
—
mixed-class rows
|
2,867,088
mixed-class rows
|
$125,591,477 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
—
mixed-class rows
|
1,619,132
mixed-class rows
|
$122,153,992 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
0.79%
|
1,527,028
|
$116,802,372 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
—
mixed-class rows
|
1,414,161
mixed-class rows
|
$107,251,104 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.72%
|
1,401,035
|
$107,165,167 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
—
mixed-class rows
|
1,404,788
mixed-class rows
|
$103,739,800 | — | 31 Dec 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.68%
|
1,314,303
|
$100,531,037 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.67%
|
1,299,346
|
$99,386,976 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.65%
|
1,270,290
|
$96,956,284 | — | 31 Dec 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.65%
|
1,263,484
|
$96,643,891 | — | 31 Dec 2025 | |
| Hood River Capital Management LLC |
13F
|
Company |
0.65%
|
1,255,185
|
$96,009,101 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
3,228,506
mixed-class rows
|
$85,083,597 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.57%
|
1,106,820
|
$84,660,766 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
mixed-class rows
|
1,082,038
mixed-class rows
|
$82,509,808 | — | 31 Dec 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
—
mixed-class rows
|
2,946,026
mixed-class rows
|
$80,657,445 | — | 31 Dec 2025 | |
| Allspring Global Investments Holdings, LLC |
13F
|
Company |
0.51%
|
994,220
|
$77,782,802 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.44%
|
858,968
|
$65,702,462 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.43%
|
841,536
|
$64,369,176 | — | 31 Dec 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
0.43%
|
826,131
|
$63,190,753 | — | 31 Dec 2025 | |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC |
13F
|
Company |
0.42%
|
813,794
|
$62,247,103 | — | 31 Dec 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
0.42%
|
810,142
|
$61,967,762 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for BridgeBio Pharma, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas Trimarchi | BBIO | Common Stock | Award | 17.5% | 59,041 | 395,626 | 18 Mar 2026 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Award | 11.6% | 14,170 | 136,115 | 18 Mar 2026 | Direct | ||
| Neil Kumar | BBIO | Restricted Stock Units | Award | 104,313 | 104,313 | 17 Mar 2026 | Direct | |||
| Neil Kumar | BBIO | Stock Option (Right to Buy) | Award | 40,570 | 40,570 | 17 Mar 2026 | Direct | |||
| Neil Kumar | BBIO | Common Stock | Sale | -0.45% | $1,375,913 | $68.80 | -20,000 | 4,438,447 | 13 Mar 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -3.05% | $1,375,890 | $68.79 | -20,000 | 635,686 | 13 Mar 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -0.45% | $1,374,660 | $68.73 | -20,000 | 4,458,447 | 12 Mar 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -2.96% | $1,374,605 | $68.73 | -20,000 | 655,686 | 12 Mar 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Hannah Valantine | BBIO | Common Stock | Sale | -53.7% | $624,312 | $72.00 | -8,671 | 7,465 | 10 Mar 2026 | Direct |
| Hannah Valantine | BBIO | Common Stock | Options Exercise | 116.2% | 8,671 | 16,136 | 10 Mar 2026 | Direct | ||
| Hannah Valantine | BBIO | Stock Option (Right to Buy) | Options Exercise | -33.3% | -8,671 | 17,343 | 10 Mar 2026 | Direct | ||
| Andrea Ellis | BBIO | Common Stock | Sale | -77.7% | $4,211,302 | $64.87 | -64,921 | 18,589 | 04 Mar 2026 | Direct |
| Andrea Ellis | BBIO | Common Stock | Options Exercise | 349.2% | 64,921 | 83,510 | 04 Mar 2026 | Direct | ||
| Andrea Ellis | BBIO | Stock Option (right to buy) | Options Exercise | -100% | -64,921 | 0 | 04 Mar 2026 | Direct | ||
| Hannah Valantine | BBIO | Common Stock | Sale | -77.3% | $1,717,781 | $67.41 | -25,484 | 7,465 | 27 Feb 2026 | Direct |
| Hannah Valantine | BBIO | Common Stock | Options Exercise | 341.4% | 25,484 | 32,949 | 27 Feb 2026 | Direct | ||
| Hannah Valantine | BBIO | Stock Option (Right to Buy) | Options Exercise | -100% | -25,484 | 0 | 27 Feb 2026 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Sale | -1.61% | $132,000 | $66.00 | -2,000 | 121,945 | 26 Feb 2026 | Direct |
| Neil Kumar | BBIO | Common Stock | Sale | -10.7% | $2,002,717 | $71.39 | -28,053 | 234,451 | 19 Feb 2026 | Direct |
| Maricel Apuli | BBIO | Common Stock | Sale | -0.41% | $37,898 | $74.31 | -510 | 123,945 | 17 Feb 2026 | Direct |
| Thomas Trimarchi | BBIO | Common Stock | Sale | -3.88% | $1,016,147 | $74.72 | -13,600 | 336,585 | 17 Feb 2026 | Direct |
| Randal W. Scott | BBIO | Common Stock | Sale | -46.3% | $754,557 | $75.46 | -10,000 | 11,589 | 17 Feb 2026 | Direct |
| Randal W. Scott | BBIO | Common Stock | Options Exercise | 86.3% | 10,000 | 21,589 | 17 Feb 2026 | Direct | ||
| Randal W. Scott | BBIO | Stock Option (Right to Buy) | Options Exercise | -24.1% | -10,000 | 31,501 | 17 Feb 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Tax liability | -10.6% | -30,970 | 262,504 | 16 Feb 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Options Exercise | 28.3% | 64,698 | 293,474 | 16 Feb 2026 | Direct | ||
| Neil Kumar | BBIO | Restricted Stock Units | Options Exercise | -32.5% | -64,698 | 134,176 | 16 Feb 2026 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Tax liability | -3.38% | -4,349 | 124,455 | 16 Feb 2026 | Direct | ||
| Thomas Trimarchi | BBIO | Common Stock | Tax liability | -5.1% | -18,819 | 350,185 | 16 Feb 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Sale | -0.44% | $1,435,544 | $71.78 | -20,000 | 4,478,447 | 11 Feb 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -2.87% | $1,435,543 | $71.78 | -20,000 | 675,686 | 11 Feb 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -0.44% | $1,438,757 | $71.94 | -20,000 | 4,498,447 | 10 Feb 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -2.79% | $1,438,822 | $71.94 | -20,000 | 695,686 | 10 Feb 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -0.44% | $1,542,115 | $77.11 | -20,000 | 4,518,447 | 09 Jan 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -2.72% | $1,542,198 | $77.11 | -20,000 | 715,686 | 09 Jan 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -0.44% | $1,479,433 | $73.97 | -20,000 | 4,538,447 | 08 Jan 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -2.65% | $1,479,422 | $73.97 | -20,000 | 735,686 | 08 Jan 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -11.6% | $2,239,902 | $74.64 | -30,011 | 228,776 | 15 Dec 2025 | Direct |
| Neil Kumar | BBIO | Common Stock | Tax liability | -10.7% | -30,964 | 258,787 | 12 Dec 2025 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Options Exercise | 26.6% | 60,975 | 289,751 | 12 Dec 2025 | Direct | ||
| Neil Kumar | BBIO | Restricted Stock Units | Options Exercise | -50% | -60,975 | 60,976 | 12 Dec 2025 | Direct | ||
| Thomas Trimarchi | BBIO | Common Stock | Tax liability | -3.61% | -13,826 | 369,004 | 12 Dec 2025 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Tax liability | -1.54% | -2,003 | 128,294 | 12 Dec 2025 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Sale | -1.51% | $148,520 | $74.26 | -2,000 | 130,297 | 08 Dec 2025 | Direct |
| Neil Kumar | BBIO | Common Stock | Sale | -0.44% | $1,466,287 | $73.31 | -20,000 | 4,558,447 | 05 Dec 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -2.58% | $1,466,276 | $73.31 | -20,000 | 755,686 | 05 Dec 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -0.43% | $1,487,954 | $74.40 | -20,000 | 4,578,447 | 04 Dec 2025 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -2.51% | $1,487,958 | $74.40 | -20,000 | 775,686 | 04 Dec 2025 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -10.3% | $1,722,224 | $65.84 | -26,156 | 228,776 | 20 Nov 2025 | Direct |
| Andrew Lo | BBIO | Common Stock | Sale | -52.1% | $3,613,069 | $65.69 | -55,000 | 50,583 | 18 Nov 2025 | By Andrew W. Lo and Nancy N. Lo JTWROS |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.